Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core

Leukemia. 2022 Jul;36(7):1926-1930. doi: 10.1038/s41375-022-01603-3. Epub 2022 May 24.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Down Syndrome* / complications
  • Histone Demethylases / metabolism
  • Humans
  • Janus Kinases / metabolism
  • Leukemia, Myeloid*
  • STAT Transcription Factors / metabolism

Substances

  • STAT Transcription Factors
  • Histone Demethylases
  • Janus Kinases